Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05156320
Other study ID # SRK-015-003
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date February 24, 2022
Est. completion date December 2024

Study information

Verified date May 2024
Source Scholar Rock, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Phase 3 trial (Study SRK-015-003) is being conducted in patients ≥2 years old at Screening, who were previously diagnosed with later-onset spinal muscular atrophy (SMA) (i.e., Type 2 and Type 3 SMA) and are receiving an approved survival motor neuron (SMN) upregulator therapy (i.e., either nusinersen or risdiplam), to confirm the efficacy and safety of apitegromab as an adjunctive therapy to nusinersen and evaluate the efficacy and safety of apitegromab as an adjunctive therapy to risdiplam.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 188
Est. completion date December 2024
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group 2 Years to 21 Years
Eligibility Inclusion Criteria: - Males and females 2 through 21 years old at Screening. - Documented diagnosis of 5q SMA. - Diagnosed with later-onset SMA (i.e., Type 2 and Type 3 SMA) before receiving an approved SMN upregulator therapy (i.e., either nusinersen or risdiplam). - Must be Nonambulatory at Screening. Nonambulatory patients must be able to sit independently (sits up straight with head erect for at least 10 seconds; does not use arms or hands to balance body or support position) per World Health Organization (WHO) motor milestones definition at Screening. - Receiving one background therapy for SMA (i.e., either nusinersen or risdiplam) for the time period specified below and anticipated to remain on that same treatment throughout the trial: 1. If receiving the SMN upregulator therapy nusinersen, must have completed at least 10 months of dosing (i.e., completed the loading regimen and at least 2 maintenance doses) before Screening; 2. If receiving the SMN upregulator therapy risdiplam, must have completed at least 6 months of dosing before Screening. - Motor Function Score (HFMSE) =10 and =45 at Screening. - Have no physical limitations that would prevent the patient from undergoing motor function outcome measures throughout the duration of the study. - Able to receive study drug infusions and provide blood samples through the use of a peripheral intravenous (IV) or a long-term IV access device that the patient has placed for reasons independent from the study throughout the duration of the study. - Able to adhere to the requirements of the protocol, including travel to the study center and completing all study procedures and study visits. - For patients who are expected to have reached reproductive maturity by the end of the study, adhere to study specific contraception requirements. Exclusion Criteria: - Received ZOLGENSMA® (onasemnogene abeparvovec-xioi) at any time and previous treatment with apitegromab. - Use of invasive ventilation and tracheostomy. - Use of chronic daytime non-invasive ventilatory support for >16 hours daily in the 2 weeks prior to dosing, or anticipated to regularly receive such daytime ventilator support chronically over the duration of the study. - Any acute or co-morbid condition interfering with the well-being of the patient within 7 days of screening, including active systemic infection, the need for acute treatment or inpatient observation due to any reason. - Severe scoliosis and/or contractures at screening. Based on clinical judgement, any scoliosis or contractures present must be stable over the past 6 months, anticipated to be stable for the duration of the study and not prevent the patient from being evaluated on any functional outcome measures throughout the duration of the study. - Pregnant or breastfeeding. - Major orthopedic or other interventional procedure, including spine or hip surgery, considered to have the potential to substantially limit the ability of the patient to be evaluated on any functional outcome measures, within 6 months prior to Screening, or anticipated for the duration of the study. - Prior history of a hypersensitivity reaction to a monoclonal antibody (mAb) or recombinant protein bearing an Fc domain (such as a soluble receptor-Fc fusion protein), apitegromab, or excipients of apitegromab. - Treatment with investigational drugs within 3 months prior to Screening. - Use of therapies with potentially significant muscle effects (such as androgens, insulin-like growth factor, growth hormone, systemic beta-agonist, botulinum toxin, or muscle relaxants or muscle-enhancing supplements) or potentially significant neuromuscular effects (such as acetylcholinesterase inhibitors) within 60 days prior to screening. - Nutritional status not stable over the past 6 months and not anticipated to be stable throughout the duration of the study. - Patient has any other condition, which in the opinion of the Investigator may compromise safety or compliance, would preclude the patient from successful completion of the study, or interfere with the interpretation of the results.

Study Design


Intervention

Drug:
Apitegromab
Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.
Placebo
Placebo will be administered every 4 weeks by intravenous (IV) infusion.

Locations

Country Name City State
Belgium UZ Gent Gent
Belgium UZ Leuven Leuven
Belgium Chr de La Citadelle Liège
France CHU Lille - Hôpital Jeanne de Flandre Lille
France Hôpital Armand Trousseau, I-Motion Paris
France CHU Toulouse - Hopital des Enfants Toulouse
Germany Universitätsklinikum Bonn Bonn
Germany Universitätsklinikum Essen Essen
Germany Universitaetsklinikum Freiburg Freiburg
Germany Dr. von Haunersches Kinderspital Munich
Italy IRCCS Istituto Giannina Gaslini Genoa
Italy A.O.U Policlinico G. Martino Messina
Italy ASST Grande Ospedale Metropolitano Niguarda Milan
Italy Foundation I.R.C.C.S. Carlo Besta Neurological Institute Milan
Italy Centro Clinico Nemo Pediatrico Policlinico A. Gemelli-Università Cattolica Sacro Cuore Roma
Netherlands Universitair Medisch Centrum Utrecht Utrecht
Poland Uniwersyteckie Centrum Kliniczne w Gdansku Gdansk
Poland Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Poznan
Poland Instytut Pomnik - Centrum Zdrowia Dziecka: CZD Warszawa Warsaw
Spain Hospital Sant Joan de Déu Barcelona
Spain Hospital Universitario y Politécnico La Fe Valencia
United Kingdom Leeds Teaching Hospitals NHS Trust Leeds
United Kingdom Great Ormond Street Hospital for Children NHS Foundation Trust London
United Kingdom University of Oxford Oxford
United States Children's Hospital Colorado Aurora Colorado
United States The Johns Hopkins University Baltimore Maryland
United States Children's of Alabama Birmingham Alabama
United States Boston Children's Hospital Boston Massachusetts
United States Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
United States Nationwide Children's Hospital Columbus Ohio
United States Children's Medical Center Dallas Dallas Texas
United States Helen DeVos Children's Hospital Grand Rapids Michigan
United States University of Iowa Iowa City Iowa
United States University of Kansas Medical Center Kansas City Kansas
United States Children's Hospital of Los Angeles Los Angeles California
United States University of Wisconsin School of Medicine and Public Health Madison Wisconsin
United States St. Jude Children's Research Hospital Memphis Tennessee
United States Columbia University, SMA Clinical Research Center New York New York
United States Children's Hospital of The King's Daughters Norfolk Virginia
United States Nemours Children's Hospital Orlando Florida
United States Stanford University Medical Center Palo Alto California
United States Childrens Hospital of Philadelphia Philadelphia Pennsylvania
United States Phoenix Children's Hospital Phoenix Arizona
United States Oregon Health & Sciences University Portland Oregon
United States Washington University School of Medicine in St. Louis Saint Louis Missouri
United States Gillette Children's Specialty Healthcare Saint Paul Minnesota
United States University of Utah Salt Lake City Utah
United States Rady's Children's Hospital/UCSD San Diego California
United States Seattle Children's Hospital Seattle Washington
United States Wake Forest Baptist Medical Center Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Scholar Rock, Inc.

Countries where clinical trial is conducted

United States,  Belgium,  France,  Germany,  Italy,  Netherlands,  Poland,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Main Efficacy Population: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) total score. The HFMSE assesses the physical abilities of patients with Type 2 and Type 3 SMA. It comprises of 33 items graded on a scale of 0, 1, or 2, where 0 denotes unable, 1 denotes performed with modification or adaptation, and 2 denotes performed without modification or adaptation. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate increased motor function. Baseline up to 12 months.
Secondary Main Efficacy Population: Proportion of patients with =3-point change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) total score. The HFMSE assesses the physical abilities of patients with Type 2 and Type 3 SMA. It comprises of 33 items graded on a scale of 0, 1, or 2, where 0 denotes unable, 1 denotes performed with modification or adaptation, and 2 denotes performed without modification or adaptation. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate increased motor function. Baseline up to 12 months.
Secondary Main Efficacy Population: Change from Baseline in Revised Upper Limb Module (RULM) total score. The RULM is a 20 item assessment of upper limb function in nonambulatory patients with SMA that was performed for patients who were 30 months of age or older at baseline. The 19 scored items assess functions that relate to everyday life, such as pressing a button and picking up a token; these items are scored 0, 1, or 2, where 0 denotes unable, 1 denotes able with modification, and 2 denotes able with no modification. The maximum score achievable is 37. Higher scores increased great upper limb function. Baseline up to 12 months.
Secondary Main Efficacy Population: Change from Baseline in number of WHO motor development milestones attained at 12 months. Baseline up to 12 months.
Secondary Main Efficacy Population and Exploratory Subpopulation combined: Incidence of Treatment Emergent Adverse Events (TEAEs) and Severe Adverse Events (SAEs) by severity. Baseline up to 12 months.
Secondary Main Efficacy Population and Exploratory Subpopulation combined: Apitegromab concentrations in serum from blood samples. Baseline up to 12 months.
Secondary Main Efficacy Population and Exploratory Subpopulation combined: Circulating latent myostatin concentrations in blood samples. Baseline up to 12 months.
Secondary Main Efficacy Population and Exploratory Subpopulation combined: Presence or absence of ADA against apitegromab in serum from blood samples. Baseline up to 12 months.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT04435093 - Digitalization Playful Module of Motor Function Measure Assessment for Children With Neuromuscular Disorders, MFM-Play Pilot Study.
Not yet recruiting NCT04089696 - Validation of the "ExSpiron©" in Patients With ALS N/A
Not yet recruiting NCT05785546 - Elaboration of a Pronostic Score of Changes on Wheelchair's Seating System
Completed NCT01313325 - Hippotherapy to Improve the Balance of Children With Movement Disorders N/A
Recruiting NCT04098094 - Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
Active, not recruiting NCT05070624 - The Peer Support Study N/A
Completed NCT04729920 - Home Use of Mechanical Insufflation/Exsufflation Devices in Neuromuscular Diseases
Recruiting NCT04581577 - Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders
Completed NCT06428864 - Effect of the Use of a 3D Scanner Application on a Smartphone to Mold Garchois Orthotic Device in Neuromuscular Diseases Patients With Scoliosis
Enrolling by invitation NCT05539456 - Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
Completed NCT05353738 - Efficacy of Vaccination Against COVID-19 in Patients Presenting a Neuromuscular Disease With Severe Amyotrophy
Recruiting NCT04541602 - Detection of Neuromuscular Complications in Critically Ill Patients
Completed NCT03394859 - Electronic Medical Records and Genomics (eMERGE) Phase III
Enrolling by invitation NCT05099107 - Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment N/A
Completed NCT05070910 - NDT Effectiveness Study N/A
Recruiting NCT04100993 - Multisystem and Autonomic Complications of NMD on Long-term NIV
Recruiting NCT04986059 - Effects of Pre-event Massage on Muscle Activity N/A
Completed NCT01022931 - Epidemiology and Clinical Presentation of H1N1 Infection in Children in Geneva N/A
Terminated NCT03353064 - Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure N/A